KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 81 filers reported holding KEROS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,127,715 | -49.1% | 98,109 | -35.8% | 0.00% | -50.0% |
| Q2 2023 | $6,141,392 | -55.9% | 152,847 | -53.1% | 0.00% | -60.0% |
| Q1 2023 | $13,922,933 | -29.6% | 326,064 | -20.9% | 0.01% | -37.5% |
| Q4 2022 | $19,789,186 | +10.5% | 412,103 | -13.4% | 0.02% | +23.1% |
| Q3 2022 | $17,912,000 | +40.2% | 476,123 | +3.0% | 0.01% | +30.0% |
| Q2 2022 | $12,775,000 | +2884.8% | 462,370 | +5773.6% | 0.01% | – |
| Q1 2022 | $428,000 | -77.2% | 7,872 | -75.5% | 0.00% | -100.0% |
| Q4 2021 | $1,879,000 | +155.3% | 32,120 | +72.7% | 0.00% | – |
| Q3 2021 | $736,000 | -58.3% | 18,602 | -55.2% | 0.00% | -100.0% |
| Q2 2021 | $1,764,000 | -32.9% | 41,544 | -2.7% | 0.00% | -50.0% |
| Q1 2021 | $2,628,000 | +1027.9% | 42,697 | +1191.5% | 0.00% | – |
| Q4 2020 | $233,000 | +1692.3% | 3,306 | +886.9% | 0.00% | – |
| Q3 2020 | $13,000 | -62.9% | 335 | -64.5% | 0.00% | – |
| Q2 2020 | $35,000 | – | 943 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |